The evolving role of mass spectrometry in drug discovery
Mass spectrometry is increasingly playing a central role as a platform to investigate biological pathways, quantify protein abundancies, look for interactions between proteins, and investigate protein modifications in healthy and disease cells. Furthermore our ability to quantify the interactions of small molecules with proteins by mass spectrometry has become mainstream and we now have MS-based lead generation platforms available. The increasing sensitivity and applicability of mass spectrometry to different molecule types has also enabled widespread use for investigating absorption, distribution and metabolism of mew modalities such as antibody drug conjugates and oligonucleotides, becoming a key technique supporting the development of these therapeutics.
In this webinar we will review the state of the art in these main areas:
- Mass spectrometry as a tool for target identification and validation, with a focus on proteomics
- Small molecule lead generation with mass spectrometry, with a focus on affinity selection mass spectrometry
- Distribution, metabolism and pharmacokinetics of new modalities through the application of mass spectrometry
Who Should Attend:
- Drug discovery scientists in academia, biotech and the pharmaceutical industry. Chemists, biologists, pharmacologists, toxicologists, DMPK scientists of all levels
Presenter: Wenzhang Chen (Senior Director, WuXi AppTec)
Presenter: Nan Zhao (Principle Scientist III, LTD DMPK, WuXi AppTec)
Presenter: Dave Madge (Vice President, WuXi AppTec)
Presenter: Penny Jia (AS-MS Project Leader, WuXi AppTec)
Presenter: Jeff Huber (Contributing Editor, C&EN Media Group)
